Xencor

XNCR

Market cap $695M

Overview Fund Activity

9.74 USD

+0.49

5.3%

At close Updated Sep 18, 12:59 PM EDT

1 day

5.3%

5 days

14.45%

1 month

24.71%

3 months

16.51%

6 months

-22.82%

Year to date

-59.06%

1 year

-53.29%

5 years

-77.36%

10 years

-47.89%

About: Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Employees: 250

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

156% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 36

3.94% more ownership

Funds ownership: 111.63% [Q1] → 115.58% (+3.94%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

4% less funds holding

Funds holding: 201 [Q1] → 192 (-9) [Q2]

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

23% less capital invested

Capital invested by funds: $837M [Q1] → $647M (-$190M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

38% downside

Avg. target

$17.2

77% upside

High target

$27

177% upside

5 analyst ratings

3 positive

60%

1 neutral

20%

1 negative

20%

Barclays Etzer Darout	$6	Underweight Assumed	17 Sep 2025
B of A Securities Alec Stranahan	$12	Neutral Downgraded	3 Sep 2025
Wedbush David Nierengarten	$26	Outperform Reiterated	2 Sep 2025
RBC Capital Leonid Timashev	$15	Outperform Maintained	21 Aug 2025
Wells Fargo Eva Fortea Verdejo	$27	Overweight Maintained	7 Aug 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?

Xencor to Participate at Upcoming Investor Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT Cantor Global Healthcare Conference 2025 Date: Thursday, September 4, 2025 Presentati.

Xencor to Participate at Upcoming Investor Conferences

Zacks Investment Research

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.07 per share a year ago.

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

The Motley Fool

Xencor (XNCR) Q2 Revenue Jumps 82%

Xencor (XNCR) Q2 Revenue Jumps 82%

Xencor (XNCR) Q2 Revenue Jumps 82%

Xencor Reports Second Quarter 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025 and provided recent business and clinical program updates. "Xencor is focused on execution of our clinical studies, evaluating four wholly owned XmAb® drug candidates in cancer and advanced autoimmune-driven diseases,” said Bassil.

Xencor Reports Second Quarter 2025 Financial Results

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., whe.

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Zacks Investment Research

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor Reports First Quarter 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a high potency investigational anti-TL1A antibody and an every 12-week subcutaneous dosing regimen during.

Xencor Reports First Quarter 2025 Financial Results

Zacks Investment Research

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Interim results fro.

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

See News Rankings

Charts implemented using Lightweight Charts™